Suchergebnisse - "Saif, Muhammad Wasif"

PubPharm (580)

71

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors

enthalten in: Journal of pancreatic cancer | 2018

von Saif, M. | Fu, J. | Smith, M. | +3

72

Telotristat ethyl : proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Masab, M. | Saif, M.

73

T cell optimization for the treatment of pancreatic cancer

enthalten in: Expert opinion on biological therapy | 2017

von Liu, F. | Saif, M.

74

Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in 2017

enthalten in: JOP : Journal of the pancreas | 2017

von Saif, M.

CommentOn: Int J Oncol. 2016 Feb;48(2):657-69. - PMID 26691441

75

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Masab, M. | Saif, M.

76

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Masab, M. | Saif, M.

77

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Masab, M. | Saif, M.

78

Second line treatment options for pancreatic cancer

enthalten in: Expert opinion on pharmacotherapy | 2017

von Passero, F. | Saif, M.

79

New therapeutic directions for advanced pancreatic cancer : cell cycle inhibitors, stromal modifiers and conjugated therapies

enthalten in: Expert opinion on emerging drugs | 2017

von Matera, R. | Saif, M.

80

Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Relias, V. | Maloney, A. | Smith, M. | +1